This category includes diseases such as epilepsy, Parkinson’s and multiple sclerosis, as well as migraines. To date, the G-BA has assessed XX different medicinal products in this therapeutic area within the scope of XX procedures, which in turn were divided into xx subpopulations. A major additional benefit has been identified for xx% of these subpopulations, with a considerable additional benefit seen for XX%. The G-BA has confirmed a minor additional benefit for XX% of the subpopulations and a non-quantifiable additional benefit for another XX% in relation to the comparative treatment. No additional benefit in relation to the comparative therapy was proved for XX% of the subpopulations weighted according to the share of resolutions, corresponding to xx% of the maximum xx million patients treatable with these medicinal products.